Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer R&D head LaMattina to advise Ziarco

He previously spent 30 years at US pharma firm

Dr John LaMattina ZiarcoUK-based biotech Ziarco has hired former head of R&D at Pfizer, Dr John LaMattina, as a strategic R&D adviser.

Dr LaMattina spent 30 years at Pfizer in total, including four years as president of global research and development from 2003 until his retirement from the US pharma giant in 2007.

Earlier roles he held at Pfizer included senior VP of worldwide development and chief medical officer.

In his new role, he will help Ziarco to advance its development strategies for its investigational compounds to tackle inflammatory and allergic diseases.

These include a H4 agonist that has just completed a phase I study.

In addition to his role at Ziarco, LaMattina is a senior partner at PureTech Venues and serves on the board of directors at Ligand Pharmaceuticals and the scientific advisory board of Trevena Pharmaceuticals.

20th March 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....